Table 3 Univariate analysis of the factors affecting platelet count and function in PD patients.

From: Platelet abnormalities in patients with Parkinson's disease undergoing preoperative evaluation for deep brain stimulation

Variables	Thrombocytopenia			Prolonged BT			Prolonged CT of PFA-100			Abnormal platelet
Variables	OR	95% CI	p value	OR	95% CI	p value	OR	95% CI	p value	OR	95% CI	p value
Age	1.058	0.952, 1.175	0.2974	1.009	0.928, 1.096	0.8406	0.980	0.917, 1.048	0.5570	0.990	0.937, 1.046	0.7211
Sex	0.264	0.052, 1.332	0.1068	1.057	0.311, 3.589	0.9290	1.175	0.427, 3.232	0.7553	0.940	0.415, 2.127	0.8813
Duration of symptoms	0.858	0.712, 1.033	0.1064	1.008	0.906, 1.123	0.8788	0.915	0.810, 1.033	0.1508	0.930	0.850, 1.018	0.1170
Hoehn and Yahr stage
Off	0.606	0.204, 1.798	0.3669	0.603	0.219, 1.661	0.3278	0.742	0.314, 1.755	0.4969	0.631	0.308, 1.291	0.2072
On	0.724	0.265, 1.981	0.5293	0.615	0.238, 1.590	0.3153	0.613	0.288,1.305	0.2044	0.554	0.288, 1.064	0.0760
UPDRS-III
Off	0.983	0.927, 1.042	0.5595	0.943	0.877, 1.014	0.1135	0.970	0.926, 1.017	0.2068	0.960	0.923, 0.999	0.0464*
On	0.992	0.917, 1.073	0.8390	1.010	0.941, 1.085	0.7810	0.960	0.902, 1.021	0.1902	0.960	0.913, 1.009	0.1069
Levodopa dosage	1.001	1.000, 1.003	0.1539	1.000	0.998, 1.001	0.6559	1.000	0.998, 1.001	0.8943	1.000	0.999, 1.001	0.7485
LEDD	1.001	0.999, 1.002	0.4051	1.000	0.999, 1.001	0.9347	1.000	0.999, 1.001	0.6157	1.000	1.000, 1.001	0.4339
PD medications
Levodopa/benserazide	0.897	0.211, 3.816	0.8835	0.538	0.153, 1.895	0.3349	0.833	0.278, 2.494	0.7444	0.705	0.295, 1.687	0.4324
Amantadine	0.596	0.155, 2.294	0.4522	0.895	0.263, 3.038	0.8585	0.994	0.361, 2.736	0.9909	1.007	0.445, 2.279	0.9875
Entacapone	0.596	0.155, 2.294	0.4522	1.789	0.494, 6.477	0.3753	0.994	0.361, 2.736	0.9909	1.007	0.445, 2.279	0.9875
Carbidoma/levodopa	0.989	0.256, 3.813	0.9866	2.076	0.600, 7.177	0.2485	1.648	0.596, 4.552	0.3356	1.668	0.733, 3.794	0.2223
Pramipexole	1.572	0.417, 5.925	0.5043	0.786	0.216, 2.855	0.7142	1.414	0.511, 3.913	0.5043	1.397	0.613, 3.182	0.4263
Ropinirole	1.619	0.414, 6.330	0.4885	1.735	0.494, 6.086	0.3897	0.867	0.277, 2.714	0.8068	1.161	0.482, 2.800	0.7388
Biperiden	0.310	0.037, 2.612	0.2814	0.254	0.031, 2.098	0.2032	0.744	0.219, 2.523	0.6349	0.372	0.116, 1.195	0.0968
Rotigotine	0.000	NA	0.9587	1.109	0.213, 5.766	0.9020	0.652	0.132, 3.230	0.6008	0.537	0.139, 2.066	0.3654
Selegiline	0.000	NA	0.9787	11.500	2.173, 60.865	0.0041*	4.313	0.796, 23.376	0.0901	4.929	1.152, 21.091	0.0315*

PD, Parkinson’s disease; BT, bleeding time; CT, closure time; PFA-100, Platelet Function Analyzer-100; OR, odds ratio; CI, confidence interval; UPDRS, Unified Parkinson’s Disease Rating Scale; LEDD, levodopa equivalent daily dose.
*Statistically significant.

Back to article page

Table 3 Univariate analysis of the factors affecting platelet count and function in PD patients.

Search

Quick links